RxDoctor Payments Data

Enrique de Leon, PA

Internal Medicine · Bakersfield, CANPI 1457449308

Payments from drug & device makers

$14,076in general payments, 2019–2025

Across 732 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • GSK$1K
  • AstraZeneca$807
  • Amgen$433
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$13,95499%
  • Education$1211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,076 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$129,654
Medicare patients
296
Services billed
2,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$92,409
JardianceEmpagliflozin93$87,765
RybelsusSemaglutide60$77,894
MounjaroTirzepatide40$44,910
LinzessLinaclotide63$35,397
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$35,299
EliquisApixaban37$31,107
TrulicityDulaglutide27$29,814
FarxigaDapagliflozin Propanediol34$27,917
JanuviaSitagliptin Phosphate28$15,431
MyrbetriqMirabegron21$9,350
TradjentaLinagliptin12$9,290
XareltoRivaroxaban14$7,694
VascepaIcosapent Ethyl23$7,439
Celecoxib78$4,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,021$170,302142 claims
Boehringer IngelheimJardiance, Tradjenta$426$97,055105 claims
Lilly USA, LLCMounjaro, Trulicity$1,452$74,72467 claims
AbbVieLinzess, Synthroid$3,255$36,42680 claims
GSKTrelegy Ellipta$1,349$35,29949 claims
PfizerEliquis$318$31,10737 claims
AstraZenecaFarxiga$807$27,91734 claims
MerckJanuvia$77$15,43128 claims
Astellas Pharma US IncMyrbetriq$149$9,35021 claims
Johnson & JohnsonXarelto$82$7,69414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →